UNSPSC 51102861: Methylprednisolone/neomycin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.

UNSPSC 51102861 Methylprednisolone/neomycin is a Commodity code, but the recent state and local opportunities posted under it do not align with the code's nominal scope. The two recent records show procurement of unrelated pharmaceutical products: Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets (Illinois Department of Public Health), and Naloxone with drug deactivation systems (Seminole County, Florida). Neither solicitation involves methylprednisolone or neomycin formulations. The code shows little relevant recent activity that matches its stated pharmaceutical category.

The Illinois opportunity, posted August 28, 2026, was a completed award to Chartwell Rx LLC for a piggyback contract through the MMCAP Infuse consortium under an Invitation for Bid process, with a total contract value of $2,999,999.11 over twelve months plus two optional renewal years. The Seminole County opportunity, posted June 30, 2026 with a response deadline of July 26, 2023, was an IFB for annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, under a two-year initial term with one-year renewal option and potential FEMA funding. The issuing bodies represent state health departments and county public health operations; no repeat buyers appear in the limited recent record. Geographic activity is limited to Illinois and Florida in the recent sample.